UNSPSC 51161519: Carmoterol

This classification denotes an antiasthmatic drug with the molecular formula C21H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9810NUL4D1, chemically known as 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one but generally known as carmoterol, which bears US NIH Compound Identifier 63952. European Medicines Agency schedules Aarmoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25400.

The term CARMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53.). Most nations schedule carmoterol under HS 29337900 and SITC 51561. As of Q4 2014, CARMOTEROL remains the US FDA Preferred Term for this commodity. SMILES: CC(CC1=CC=C(C=C1)OC)NCC(C2=C3C=CC(=O)NC3=C(C=C2)O)O.

UNSPSC 51161519 Carmoterol, a Commodity code, covers pharmaceutical products procured through cooperative purchasing vehicles and state health procurement channels for distribution across multiple jurisdictions. State and local governments buy this drug—a long-acting beta-2 agonist used in respiratory treatment—primarily through multistate cooperative purchasing alliances that consolidate demand and establish master agreements with pharmaceutical manufacturers and authorized wholesalers. The issuing bodies are state procurement offices administering cooperative purchasing programs that serve participating state agencies, local health departments, correctional facilities, and other public health entities across multiple states. Recent solicitations require vendors to hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with authorized wholesalers, and offer flexible pricing structures including flat-price, net-price, and WAC-minus formats.

The Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, serving participating jurisdictions in Minnesota, Oregon, and other member states. The MMCAP RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (weighted at 75 percent in evaluation), with awarded vendors effective July 1, 2026 for a two-year initial term. The cooperative structure and multistate scope indicate that activity under this code clusters around established multistate purchasing alliances rather than individual state or local solicitations, with geographic reach across the upper Midwest and West.